Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb’s $2.3 Billion Acquisition of IFM Therapeutics. Small molecule biotech companies fetching trophy values from large Pharma

Leave a Reply

Your email address will not be published.